CELL INTELLIGENCE · 肿瘤细胞治疗研究

多发性骨髓瘤感染风险增加的免疫生物标志物

Immune biomarkers of increased infection risk in multiple myeloma.

多发性骨髓瘤患者对 SARS-CoV-2 二价加强针疫苗接种次优免疫应答相关的细胞机制

Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.

我们的研究强调了 MM 患者在接受二价 COVID-19 疫苗接种后观察到的不同免疫反应。具体而言，一部分接受抗 CD38 和抗 BCMA 治疗的 MM 患者经历免疫细胞如 DCs、B 细胞、NK 细胞和 TFH 细胞的损伤，导致无法对疫苗接种产生足够的体液和细胞反应。

通过单细胞测序鉴定复发/难治性多发性骨髓瘤中 BCMA CAR-T 治疗后复发的潜在耐药机制和治疗靶点

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myelom

四重基因工程化 NK 细胞实现多抗原靶向，产生针对多发性骨髓瘤的持久抗肿瘤活性

Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma.

BCMA 靶向生物疗法：多发性骨髓瘤治疗的下一个标准治疗方案

BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.

肾脏病学趋势：从虚无主义到抗体介导排斥反应的靶向治疗

Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.

多发性骨髓瘤与重型 SARS-CoV-2 感染的机制互作：间充质干细胞来源细胞外囊泡的治疗前景

Mechanistic Interplay Between Multiple Myeloma and Severe SARS-CoV-2 Infection: Therapeutic Promise of Mesenchymal Stem Cell-Derived Extracellular Ves

多发性骨髓瘤 CAR-NK 细胞治疗的最新进展：细胞来源与靶抗原的综合综述

State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.

CAR-T 与 CAR NK 细胞的在靶脱瘤效应差异提示细胞治疗的疗效与安全性不同

Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies.

多发性骨髓瘤当前的新型靶向治疗策略

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.